Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Moderna’s COVID-19 Vaccine Packaging Poses Booster Tracking, Safety Surveillance Challenges, Experts Say

Executive Summary

Since company is using same vial and NDC code for primary series and booster dose, which is half the amount, immunization registries will not be able to capture how much Moderna vaccine an individual actually gets for their third dose.

You may also be interested in...



US CDC Panel Supports Moderna, Janssen COVID Vaccine Boosters But Strips Out Preference Language For Homologous Dosing

ACIP pushes back on proposed policy recommendation that the same product used for the primary regimen should be used for the booster, saying risk/benefit and other considerations necessitate more flexibility afforded by 'mix and match' approach.

Moderna, Janssen And ‘Mix & Match’ Boosters Create A ‘Not Simple’ Array Of Dosing Options

After US FDA authorization for additional COVID vaccine shots, the focus now shifts to CDC’s advisory committee, which may be concerned about variations in eligible populations, timing and dosing when it comes to giving a booster different from the primary vaccination series.

Cancer Drug Dose Optimization Benefits Include Better Pivotal Trial Retention, Fewer Clinical Holds

US FDA is asking oncology sponsors for randomized studies comparing at least two doses early in development; despite concerns about delaying approval, FDA and industry reps say approach will increase success of registrational trials and reduce likelihood of market withdrawal due to toxicity.

Topics

Related Companies

UsernamePublicRestriction

Register

PS145148

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel